Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches.
J Pharm Pharm Sci
; 27: 13065, 2024.
Article
in En
| MEDLINE
| ID: mdl-38903652
ABSTRACT
Excess adiposity can contribute to metabolic complications, such as type 2 diabetes mellitus (T2DM), which poses a significant global health burden. Traditionally viewed as a chronic and irreversible condition, T2DM management has evolved and new approaches emphasizing reversal and remission are emerging. Bariatric surgery demonstrates significant improvements in body weight and glucose homeostasis. However, its complexity limits widespread implementation as a population-wide intervention. The identification of glucagon-like peptide 1 (GLP-1) and the development of GLP-1 receptor agonists (GLP-1RAs) have improved T2DM management and offer promising outcomes in terms of weight loss. Innovative treatment approaches combining GLP-1RA with other gut and pancreatic-derived hormone receptor agonists, such as glucose-dependant insulinotropic peptide (GIP) and glucagon (GCG) receptor agonists, or coadministered with amylin analogues, are demonstrating enhanced efficacy in both weight loss and glycemic control. This review aims to explore the benefits of bariatric surgery and emerging pharmacological therapies such as GLP-1RAs, and dual and triple agonists in managing obesity and T2DM while highlighting the caveats and evolving landscape of treatment options.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Diabetes Mellitus, Type 2
/
Bariatric Surgery
/
Obesity
Limits:
Humans
Language:
En
Journal:
J Pharm Pharm Sci
/
J. pharm. pharm. sci
/
Journal of pharmacy & pharmaceutical sciences
Journal subject:
FARMACIA
/
FARMACOLOGIA
Year:
2024
Document type:
Article
Affiliation country:
Canadá
Country of publication:
Suiza